|
?:authorAffiliation
|
-
[\'Department of Immunisations, Vaccines, and Biologicals, WHO, Geneva, Switzerland. Electronic address: feikind@who.int.\', \'International Vaccine Access Center, Department of International Health, John Hopkins Bloomberg School of Public Health, Baltimore, MA, USA.\', \'Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Doha, Qatar.\', \'UK Health Security Agency, London, UK.\', \'Instituto de Ciencias e Innovacion en Medicina, Facultad de Medicina, Clinica Alemana Universidad del Desarrollo, Santiago, Chile; Advanced Centre for Chronic Diseases, Santiago, Chile.\', \'Technion Israel Institute of Technology, Haife, Israel.\', \'National Institute for Communicable Diseases, Division of the National Health Laboratory Service, Johannesburg, South Africa; School of Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.\', \'The Gertner Institute for Epidemiology and Health Policy Research, Sheba Medical Centre, Tel Aviv University, Tel Aviv, Israel.\', \'Department of Immunisations, Vaccines, and Biologicals, WHO, Geneva, Switzerland.\', \'MRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical Medicine, London, UK.\', \'Department of Epidemiology, John Hopkins Bloomberg School of Public Health, Baltimore, MA, USA.\']
|
![[This page as RDF]](https://research.tib.eu/covid-19/static/rdf-icon.gif){kind=icon}